Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 39.96 USD 1.45%
Market Cap: 15.4B USD
Have any thoughts about
Moderna Inc?
Write Note

Moderna Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Moderna Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Moderna Inc
NASDAQ:MRNA
Revenue
$5.1B
CAGR 3-Years
-25%
CAGR 5-Years
129%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Moderna Inc
Revenue Breakdown

Breakdown by Geography
Moderna Inc

Total Revenue: 6.8B USD
100%
Rest Of World: 3.6B USD
52.5%
United States: 1.9B USD
27.7%
Europe: 1.4B USD
19.8%

Breakdown by Segments
Moderna Inc

Total Revenue: 6.8B USD
100%
Net Product Sales: 6.7B USD
97.4%
Other Revenue: 177m USD
2.6%
Grant Revenue: 94m USD
1.4%
Collaboration Revenue: 83m USD
1.2%
Show More
Show Less

Moderna Inc
Glance View

Market Cap
15.4B USD
Industry
Biotechnology
Economic Moat
None

In the vibrant world of biotechnology, Moderna Inc. stands as a remarkable testament to the fusion of cutting-edge science and swift innovation. Founded in 2010 and based in Cambridge, Massachusetts, Moderna has crafted its niche in messenger RNA (mRNA) technology, pivoting the traditional paradigms of drug development. The company’s unique approach utilizes synthetic mRNA to direct cells in the body to produce proteins that can prevent, treat, or cure diseases. This innovative platform enables rapid testing and development of medicines across a wide array of therapeutic areas, from infectious diseases to oncology, leveraging its flexible technology to address significant unmet medical needs. Moderna’s story gained global prominence in the context of the COVID-19 pandemic, when its vaccine, one of the first to be authorized, became crucial in combatting the virus, highlighting the potential of mRNA technology on a global stage. Financially, Moderna’s business model is driven by a combination of strategic partnerships, robust research and development capabilities, and the commercialization of its mRNA products. The company collaborates extensively with government agencies, global health organizations, and biopharmaceutical enterprises to both advance its pipeline and maximize its market reach. Revenue is primarily generated through the sale of its COVID-19 vaccine, alongside income from grants and collaboration agreements. Moreover, Moderna continually invests in expanding its mRNA platform and portfolio, seeking long-term value creation by targeting diverse therapeutic areas such as rare diseases, autoimmune disorders, and personalized cancer vaccines. By reinvesting in innovation and scaling its manufacturing capabilities, Moderna is not just a quintessential biotech enterprise but a harbinger of a new era in medical science.

MRNA Intrinsic Value
48.53 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Moderna Inc's Revenue?
Revenue
5.1B USD

Based on the financial report for Sep 30, 2024, Moderna Inc's Revenue amounts to 5.1B USD.

What is Moderna Inc's Revenue growth rate?
Revenue CAGR 5Y
129%

Over the last year, the Revenue growth was -44%. The average annual Revenue growth rates for Moderna Inc have been -25% over the past three years , 129% over the past five years .

Back to Top